ANX Mast Therapeutics, Inc.

BeaconEquity.com announces an investment report featuring biopharmaceutical company ADVENTRX Pharmaceuticals Inc. (AMEX:ANX). The report includes financial, comparative and investment analysis, and pertinent industry information you need to know to make an educated investment decision. 

It is available at: http://www.beaconequity.com/i/ANX

Get our alerts BEFORE the rest of the market.  Follow us on Twitter: http://twitter.com/BeaconEquity

ADVENTRX Pharmaceuticals Inc. (ANX) is a development-stage biopharmaceutical company. The Company's business is focused on in-licensing, developing and commercializing product candidates for the treatment of cancer. Its lead product candidates, ANX-530 and ANX-514, are emulsion formulations of marketed chemotherapy drugs. ANX is focused primarily on evaluating strategic options, including the sale or exclusive license of one or more of its product candidate programs, a strategic business merger and other similar transactions. In October 2008, ANX announced that it had discontinued active work on all product candidates other than ANX-530 and ANX-514.

In the report, the analyst notes:

"For the three months ended September 30, 2009, ANX's net loss applicable to common stock was $2.7 million, or 2 cents per share, compared with a net loss applicable to common stock of $6.8 million, or 8 cents per share, for the comparable period in 2008. Included in the net loss applicable to common stock for the 2009 third quarter was a non-cash deemed dividend expense of $0.4 million incurred in connection with the Company's July and August 2009 equity financings.

"ANX in early March announced that it received a refuse to file letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ANX-530 (vinorelbine injectable emulsion). ANX plans to meet with the FDA as soon as possible to discuss its response."

Read the entire report: http://www.beaconequity.com/i/ANX

See what investors are saying about ANX at penny stock forum

BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com

Beacon Equity Disclosure

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority.  We are neither licensed nor qualified to provide investment advice. Beacon Equity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities.  We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

CONTACT: Beacon Equity Research

Jeff Bishop

(469)-252-3505

press@beaconequity.com